Ipamorelin
A pentapeptide ghrelin receptor agonist and selective GH secretagogue. Studied for its targeted GH-releasing properties with minimal impact on cortisol, prolactin, or appetite signaling compared to earlier secretagogues.
Unit Price
Sign in to view pricing.
Purchase requires a verified researcher account and a signed RUO attestation.
All batch test results and certificates of analysis are published below — including any batches that failed testing. Full transparency is our standard.
Mechanism of Action
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively agonizes the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Developed by Novo Nordisk from the GHRP-1 scaffold, it was the first GHRP-receptor agonist with GH-release selectivity comparable to GHRH. Unlike GHRP-6 or GHRP-2, it produces GH release without meaningful stimulation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses >200x the ED50 for GH release.
Research References
Full research page →Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PMID: 9849822
Gobburu JV et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999
Johansen PB et al. Ipamorelin, a new growth-hormone-releasing peptide. Pharmacological studies
Beck DE et al. Prospective, Randomized, controlled proof of concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014
Related Products
Batch History & Certificates of Analysis
Full Batch Record
No batch records available for this product yet.
For Research Use Only. This product is supplied exclusively for in vitro research, laboratory study, and experimental purposes. It is not a drug, supplement, food, or cosmetic, and is not intended for human or veterinary use. See our Compliance & RUO Policy.